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Human genes coding for pLG72 and D-amino acid oxidase
have recently been linked to the onset of schizophrenia. pLG72
was proposed as an activator of the human FAD-containing fla-
voprotein D-amino acid oxidase (hDAAO). In the brain this oxi-
dizes D-serine, a potent activator ofN-methyl-D-aspartate recep-
tor.Wehave investigated themechanistic regulation of hDAAO
by pLG72. Immunohistochemical analyses revealed that
hDAAO and pLG72 are both expressed in astrocytes of the
human cortex, where theymost likely interact, considering their
partial overlapping subcellular distribution and their coimmu-
noprecipitation. We demonstrated that the specific in vitro
interaction of the two proteins yields a complex composed of 2
hDAAO homodimers and 2 pLG72 molecules. Binding of
pLG72 did not affect the kinetic properties and FAD binding
ability of hDAAO; instead, a time-dependent loss of hDAAO
activity in the presence of an excess of pLG72 was found. The
binding affects the tertiary structure of hDAAO, altering the
amount of the active form. We finally demonstrated that over-
expression of hDAAO in glioblastoma cells decreases the levels
of D-serine, an effect that is null when pLG72 is coexpressed.
These data indicate that pLG72 acts as a negative effector of
hDAAO. Therefore, a decrease in the synaptic concentration of
D-serine as the result of an anomalous increase in hDAAOactiv-
ity related to hypoexpression of pLG72 may represent a molec-
ular mechanism by which hDAAO and pLG72 are involved in
schizophrenia susceptibility.
Schizophrenia is one of the most widely spread psychiatric
disorders; it is a complex disease or, more likely, a group of
related illnesses to which an individual has a strong genetic
predisposition (1). Among the identified schizophrenia suscep-
tibility genes (2), the gene G72 encodes for several splicing iso-
forms; pLG72 represents the longest open reading frame (153
amino acids), which is mainly expressed in brain (3). G72 is
present only in primates: there are no homologues of this gene
in databases nor has sequence analysis of the putative open
reading frame revealed any likely function (2, 3). Yeast two-
hybrid experiments using pLG72 as bait identified D-amino
acid oxidase (EC 1.4.3.3, DAAO4) on 12q24 as a putative inter-
acting partner, and preliminary functional measurements
showed that pLG72 should function as an in vitro activator of
pig kidney DAAO (pkDAAO) (3). DAAO is a FAD-contain-
ing flavoenzyme that catalyzes the oxidative deamination of
D-amino acids to the corresponding -keto acids, hydrogen
peroxide and ammonia (4, 5).
Based on current findings we can hypothesize that in brain,
the physiological role of DAAO is to modulate the levels of
D-serine, an important glial-derived messenger that acts as the
endogenous allosteric modulator of the glutamatergic NMDA
receptor subtype (6–8). D- and L-serine can be reversibly
isomerized in astrocytic glia, which unsheathes synapses, by
serine racemase. Compelling evidence has indicated that gluta-
mate neurotransmission hypofunction is associatedwith symp-
toms of schizophrenia. D-Serine levels are inversely related to
the regional expression of DAAO during development (6) and
application of DAAO to brain slices or cell cultures has a con-
siderable effect on NMDA receptor-dependent synaptic trans-
mission and long term plasticity (9–12) or protects neurons
from theNMDA receptor-related excitotoxicity (13–15). Adult
DAAO-deficient mice display an increase in D-serine levels,
especially in areas where levels are normally low (16). The asso-
ciation between alterations in D-serine metabolism and schizo-
phrenia is further supported by studies demonstrating
decreased D-serine levels in the cerebrospinal fluid and serum
of schizophrenia patients. It is noteworthy that clinical trials
have demonstrated a benefit of adding D-serine to the antipsy-
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chotic regimen for treating schizophrenia and bipolar disorders
(17).
The physiopathologic hypothesis proposed by Chumakov
et al. (3) suggests that increasing the endogenous level of pLG72
could lower NMDA-type glutamate receptor activity through
DAAO activation and subsequent D-serine depletion, resulting
in hypofunction of glutamatergic synapses and, thus, predis-
posing these individuals to schizophrenia (see “Discussion”).
To provide biochemical evidence supporting the involvement
of the identified genes in this pathologic process, we recently
reported on the overexpression of pLG72 and human DAAO
(hDAAO) in Escherichia coli and biochemically characterized
hDAAO (18, 19). In the present study we have investigated the
interaction of pLG72 with hDAAO in vitro and the effect of
pLG72 binding on the functional and structural properties of
the flavoenzyme as well as their effect on the cellular concen-
tration of D-serine. We also investigated the cellular and sub-
cellular distribution of pLG72 and hDAAO by immunofluores-
cence in human cortex and in pure human astrocyte cultures.
EXPERIMENTAL PROCEDURES
hDAAO and pLG72 Purification—The recombinant
hDAAO was expressed in E. coli cells and purified as reported
in Molla et al. (19); see Fig. 1A. The final enzyme preparation
was stored in 20 mM Tris-HCl buffer, pH 8.0, 100 mMNaCl, 5%
glycerol, 5 mM 2-mercaptoethanol, and 40 M FAD. The G72
gene was also expressed in E. coli cells; the protein was
expressed in the insoluble fraction and then solubilized and
purified according to the procedure reported in Molla et al.
(18); see Fig. 1A. This final protein preparation was stored in 20
mM Tris-HCl, pH 8.5, 100 mM NaCl, 5% glycerol, and 5 mM
2-mercaptoethanol and contained 0.1% N-lauroylsarcosine
(NLS). The absorbance spectrum of the refolded and purified
pLG72 shows a maximum at 271 nm, whereas the absorbance
maximum for the unfolded form is centered at 267 nm (18).
Near- and far-UV CD spectra were also used to demonstrate
that the refolded protein acquired the secondary and tertiary
structure; see below and Ref. 18. hDAAO and pLG72 protein
concentrations were determined according to their extinction
coefficients (18, 19). Recombinant yeastDAAO (RgDAAO)was
purified from E. coli cells as reported in (20). The critical
micelle concentration of detergent NLS (2.8 mM) was not sig-
nificantly affected by the composition of the buffer used (the
amount of NLS used in most experiments, 0.06%, corresponds
to 2 mM concentration). pkDAAO was purchased from Fluka
and used after extensive dialysis against 20 mM sodium pyro-
phosphate buffer, pH 8.0, 2% glycerol, and 10 M FAD.
Kinetic and Spectral Analysis—The apparent kinetic param-
eters of hDAAO on D-serine (in the absence or in the presence
of pLG72) were determined by measuring the oxygen con-
sumption by means of a Hansatech oxygen electrode in 20 mM
Tris-HCl, pH 8.5, 150 mM NaCl, 5% glycerol, 5 mM 2-mercap-
toethanol (buffer A)with orwithout 0.06%NLS and 40MFAD
at 25 °C and air saturation. One DAAO unit is defined as the
amount of enzyme that converts 1 mol of D-amino acid per
min at 25 °C (20). The amount of catalytically active hDAAO
after the binding of pLG72 was evaluated on the basis of the
amount of FAD cofactor that can be reduced by the substrate
under anaerobic conditions. This value was determined from
the change in absorbance at 455 nm after the anaerobic addi-
tion of 1 mM D-serine to hDAAO solutions (15 M) containing
different amounts of pLG72 and free FAD. A similar assay was
used to assess the effect of different amounts of pLG72FAD
complex on the rate of flavin binding to the apoprotein form of
hDAAO (8 nmol); the binding was followed by means of the
substrate-induced reduction of the flavin at 455 nm under
anaerobic conditions.
Circular dichroism spectra were recorded with a J-815 Jasco
spectropolarimeter at 15 °C and were further analyzed with the
Jasco software; samples contained 0.4mg/ml (10M) of protein
in buffer A plus 0.06%NLS. The binding constants for FAD and
chlorpromazine (CPZ) were determined by titrating the
apoprotein form of hDAAO (1 M) or pLG72 (4 M) with
increasing amounts of ligands and by monitoring the reconsti-
tution by following the quenching of protein fluorescence at
342 nm. 8-Anilino-naphthalene-1-sulfonate binding experi-
ments were carried out at 15 °C and at 0.1 mg/ml protein con-
centration by measuring emission spectra in the 450–600-nm
range with excitation at 370 nm. Binding of this probe to sol-
vent-accessible clusters of nonpolar side chains in proteins
results in a marked increase in its fluorescence, and the emis-
sion fluorescence maximum shows a blue shift.
Determination of the hDAAOpLG72 Complex Oligomeric
State—The oligomeric state of free and complexed hDAAO
was determined by gel permeation chromatography on a
Superdex 200 column (GE Healthcare) using buffer A to which
40MFAD and 0.06%NLSwas added as the elution buffer. The
detergent was required because the solubility and the oligo-
meric state of pLG72 strongly depends on the presence of NLS;
the recovery of refolded pLG72 protein in the absence of deter-
gent in the elution buffer was low (20%), and the protein
largely eluted with the void volume, whereas at a NLS concen-
tration 0.06% pLG72 is quantitatively recovered in a single
peak with an elution volume of 15 ml. Concerning hDAAO,
we previously demonstrated that the holoenzyme and apopro-
tein (apohDAAO) forms are present as a 80-kDa homodimer
(19). The addition of up to 0.06% NLS to hDAAO does not
affect its elution volume, andmore than 70% of the initial enzy-
matic activity is recovered after chromatographic separation;
this amount of NLS was, thus, used in all the experiments. The
area of each peak was estimated by nonlinear curve-fitting of
the elution profile using PeakFit software (Systat Software) (Fig.
1B); the error was10% as estimated using known amounts of
DAAO as standard protein (5–100 nmol/run). The amount of
pLG72 and hDAAO present in the peak corresponding to the
complex was estimated bymeans of the intensity of their bands
after SDS-PAGE, as obtained using the program Quantity One
(Bio-Rad) and a known amount of purified hDAAO and pLG72
as standard (in the 0.2–20 g/lane range).
Western Blot Experiments—For Far Western blot experi-
ments, 2–10 g of pLG72 separated by SDS-PAGE electro-
phoresis were blotted onto nitrocellulose membrane, which
was then blocked with 1% bovine serum albumin (BSA) and
incubated with a 2–20-fold molar excess of hDAAO in binding
buffer (20 mM potassium phosphate buffer, pH 7.0, 150 mM
NaCl, and 1%BSA) for 60min at room temperature, with gentle
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stirring. Alternatively, purified pLG72was adsorbed on a nitro-
cellulose membrane, blocked with binding buffer, and then
overlaid with DAAO from different sources (dot Far Western
blot). In both cases and after the unboundproteinwas removed,
the membrane was incubated with anti-DAAO antibodies and
followed by secondary antibodies conjugated to alkaline phos-
phatase, as detailed in Molla et al. (20).
For quantitative pulldown experiments, 8 g of commercial
affinity-purified polyclonal goat antibodies raised against a pep-
tide mapping at the N terminus end of pLG72 ((G72(N-15);
Santa Cruz Biotechnology) were covalently cross-linked to 50
l of Dynabeads protein G (Invitrogen) and used to immuno-
precipitate protein samples containing 0.1 nmol of recombi-
nant pLG72 (1.8 g) and increasing amounts of recombinant
hDAAO (from 0 to 0.8 nmol, corresponding to 32g). Proteins
were diluted in cell homogenization buffer (25 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1 mM EDTA, 100 g/ml phenylmethyl-
sulfonyl fluoride, 0.7g/ml pepstatin, 1g/ml leupeptin, 0.06%
NLS, 10 M FAD) and incubated for 45 min at room tempera-
ture before precipitation. The amount of hDAAO precipitated
by Dynabeads-bound pLG72 was revealed by SDS-PAGE and
Western blot analysis using anti-hDAAO antibodies (affinity-
purified polyclonal rabbit antibodies raised against the recom-
binant hDAAO; Davids Biotechnologie) and quantified by den-
sitometric analysis.
Surface Plasmon Resonance Analysis—For the surface plas-
mon resonance analysis, a BIAcore X system was used as
described in Ruzzene et al. (21). hDAAO was covalently cou-
pled to aCM5 sensor chip (carboxymethylated dextran surface)
by amine-coupling chemistry to a final density of 700 resonance
units; a flow cell with no immobilized protein was used as a
control. The pLG72 solutions were injected under the condi-
tions specified in the figure legend by using HBS-EP buffer (10
mM Hepes, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% P20 (GE
Healthcare)) or 20 mM Tris-HCl buffer, pH 8.5, containing 150
mM NaCl, 0.06% NLS, and 40 M FAD; each sensorgram (time
course of the surface plasmon resonance signal) was corrected
for the response obtained in the control flow cell and normal-
ized to base line. Experiments were also carried out using
immobilized pLG72 and circulating hDAAO. After each injec-
tion the surface was regenerated by injecting 100mMNaOH for
1 min; this treatment restored the base line to the initial reso-
nance unit value. The kinetic data were analyzed using the
BIAevaluation 3.0 surface plasmon resonance kinetic software
(BIAcore).
HumanTissues andCell Cultures—Frozen human cortex tis-
sues and primary astrocyte cultures derived from human fetal
thalamus were a kind gift of Vincent Prevot (INSERM, Lille,
France). Frozen human cortex was kept at 80 °C until use.
Primary astrocyte cultures and U87 human glioblastoma cells
(ATCC)were grown to near confluence in flasks at 37 °C in a 5%
CO2 incubator in minimal essential medium (Invitrogen) sup-
plemented with 10% fetal bovine serum, 6 g/liter glucose, 2 mM
L-glutamine, 1 mM sodium pyruvate, penicillin-streptomycin,
and Fungizone.
Immunoblot andCoimmunoprecipitationAnalyses—Tissues
were homogenized in ice-cold cell homogenization buffer (see
above), sonicated (twice for 10 s with 30 s incubation in ice),
clarified by centrifugation (13,000 rpm, 30 min, 4 °C), and
stored at 80 °C. Protein extracts were subjected to 8–15%
acrylamide SDS-PAGE analysis (200g protein/lane) and elec-
troblotted onto a polyvinylidene difluoride membrane (Immo-
bilon-P, Millipore). The membranes were incubated for 2 h in
blocking solution containing 4% dried milk in Tris-buffered
saline (TBS; 10 mM Tris-HCl, pH 8.0, 500 mM NaCl) and 0.1%
Tween (TTBS) and then incubated for 1.5 h at room tempera-
ture with anti-DAAO (diluted 1/3000; Davids Biotechnologie)
or anti-pLG72 antibodies (G72(N15), diluted 1/1500; Santa
Cruz Biotechnology). Membranes were washed extensively in
TTBS containing 2% dried milk and then incubated for 1 h at
room temperature with peroxidase-conjugated donkey anti-
rabbit or anti-goat immunoglobulins (1/15000; Jackson
ImmunoResearch); immunoreactivity was then determined by
enhanced chemiluminescence (GE Healthcare). Protein con-
tent was measured by the Lowry method using the Bradford
reagent (Sigma). Controls included incubation with antibodies
preabsorbed with hDAAO or pLG72.
For coimmunoprecipitation experiments, TrueBlot anti-rab-
bit Ig immunoprecipitation beads (a suspension of activated
agarose beads coupled with goat anti-rabbit IgG; eBioscience)
were used; 500 l of human cortex crude extract (20 mg pro-
tein/ml) were subjected to preclearing by the addition of 50 l
of anti-rabbit IgG beads. Then 5 g of primary antibodies
(affinity-purified rabbit anti-hDAAOor anti-pLG72 antibodies
raised against the C-terminal end of the protein; Davids Bio-
technologie) were added to the precleared crude extract and
incubated overnight at 4 °C; the antigen-antibody complex was
then precipitated by centrifugation at 10,000 rpm for 1 min.
The beads were washed 3 times with 500 l of homogenization
buffer and subsequently resuspended in 100 l of 25 mM Tris-
HCl, pH 6.7, 6% SDS, 10% glycerol, and 50 mM dithiothreitol.
The samples were heat-denatured and centrifuged at 10,000
rpm for 3 min; then 40 l of the supernatant was separated by
SDS-PAGE and transferred onto a polyvinylidene difluoride
membrane. The membrane was developed as detailed in the
TrueBlot protocol using goat anti-pLG72 G72(N15) antibodies
and, after stripping, using anti-hDAAO antibodies (dilution as
above). The membrane was blocked overnight at 4 °C with 5%
dried milk in TrueBlot buffer (25 mM Tris-HCl, pH 7.3, 0.15 M
NaCl, 0.1% Tween 20) and subsequently incubated with pri-
mary antibodies diluted in 5% dried milk in TrueBlot buffer for
2 h at room temperature. After extensive washing, the mem-
brane was incubated for 1 h at room temperature with rabbit
IgG TrueBlot (1:1000 dilution in 5% dried milk in TrueBlot
buffer); finally, a horseradish peroxidase conjugated anti-goat
or anti-rabbit IgG immunoblotting reagent that preferentially
detects the nonreduced rabbit IgG form (thereby minimizing
interference by the heavy and the light chain of the immuno-
precipitating antibodies) was used to visualize the complex.
Immunoreactivity was determined by enhanced chemilumi-
nescence. Controls included incubation without primary anti-
bodies as well as without crude extracts.
Immunostaining on Slices from Human Cortex—Sections
fromhuman cortexwere cut serially to a 50-mthickness using
a cryostat and then mounted on Superfrost Plus glass slides.
The brain sections were then used for immunofluorescence
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analysis as previously described (22). Briefly, after extensive
washing and quenching of autofluorescence, nonspecific bind-
ing sites were blocked, and tissues were permeabilized by incu-
bation with 4% normal goat serum (NGS) and 0.2% Triton
X-100 in PBS for 1 h at room temperature. For immunofluores-
cence staining, slides were incubated for 24–48 h at 4 °C with
the following antibodies diluted in PBS plus 4% NGS and 0.1%
Triton X-100: rabbit polyclonal anti-DAAO (diluted 1/200;
Davids Biotechnologie), rabbit polyclonal anti-pLG72 (diluted
1/50; Davids Biotechnologie), rabbit polyclonal anti-glial fibril-
lary acidic protein (GFAP; diluted 1/500; Sigma), and mouse
monoclonal anti-glutamine synthase (GS; diluted 1/200;
Chemicon) or anti-S100 (diluted 1/1000; Sigma) antibodies.
After washing in PBS plus 1%NGS, the sections were incubated
with goat anti-rabbit Alexa 546-conjugated antibodies and/or
donkey anti-mouse Alexa 488-conjugated antibodies (Molecu-
lar Probes) for 1 h at room temperature. When paired rabbit
polyclonal antibodies were used in double immunofluorescent
staining, the Zenon Rabbit IgG Labeling kit (Molecular Probes)
was employed according to the company’s protocol using the
Alexa 594- and 488-labeled Fab fragments complexed with the
primary antibody. Finally, the sections were washed 3 times in
PBS supplemented with 1% NGS and three times with PBS
alone before being mounted in Vectashield mounting medium
(Vector Laboratories).
Immunostaining on Secondary Human Astrocyte Cultures—
Primary human astrocytes grown in flasks were detached with
trypsin and were plated onto poly-L-lysine-coated glass cover-
slips at a density of 0.5 105 cells/ml. After 1 week, secondary
astrocyte cultures were ready for staining. Cells were exten-
sively washed with PBS and fixed with 4% paraformaldehyde
and 0.25% glutaraldehyde in 0.1 M sodiumphosphate buffer, pH
7.4, for 30 min at room temperature. Immunofluorescence on
cells was performed as previously described for brain sections
and according toMothet et al. (23) with the only exception that
horse serum was used instead of NGS. Immunostaining was
performed by incubating the coverslips with paired antibodies
for 24 h at 4 °C; both the rabbit anti-DAAO (diluted 1/50) and
the goat anti-pLG72 (diluted 1/20) antibodies were simulta-
neously analyzed with commercial antibodies against specific
markers of subcellular compartments, such as PMP70 for per-
oxisomes (rabbit polyclonal antibody, diluted 1/400; Sigma),
58K Golgi protein and GM130 for Golgi apparatus, and lyso-
some-associated membrane protein 2 for lysosomes (mouse
monoclonal antibodies, diluted 1/500, 1/200, and 1/100,
respectively; Abcam). Immunoreactivity was demonstrated
with donkey anti-rabbit Alexa 647-, chicken anti-goat Alexa
488-, donkey anti-mouse Alexa 488-, and donkey anti-goat
Alexa 647-conjugated antibodies (diluted 1/1000; Molecular
Probes). The specific stain of mitochondria was obtained by
using MitoTracker Green FM (Molecular Probes), a green flu-
orescent dye that localizes to this compartment regardless of
the mitochondrial membrane potential; after incubation with
the secondary antibody, the coverslips were incubated for 20
min at room temperature in 30 nMMitoTracker Green FM and
extensively washed with PBS. The double immunostaining
experiments were performed using the rabbit anti-PMP70 and
anti-hDAAO antibodies (1 g) labeled with Alexa 594- and
488-tagged Fab fragments, respectively (Zenon Rabbit IgG
Labeling kit; Invitrogen). After extensive washes the coverslips
were mounted with Vectashield mounting medium (Vector
Laboratories).
Immunofluorescence from brain sections and astrocyte cul-
tures was visualized using an upright or inverted laser-scanning
confocal microscope (TCS SP2, Leica Microsystems, Mann-
heim,Germany) equippedwith a 63.0/1.25NAplan apochro-
mate oil immersion objective. The confocal images were
acquired using the Leica TCS software with a sequential mode
(if necessary) to avoid interference between each channel and
without saturating any pixel. Controls included omission of pri-
mary antibodies and incubation in immune serumpreadsorbed
on the antigen. These control sections did not display any stain-
ing. Quantitative colocalizationwas determined using the colo-
calization plug-in of ImageJ software (rsb.info.nih.gov/ij).
Measured colocalization was corrected for random colocaliza-
tion by superimposing a mirror image of the second channel
onto the image of the first channel (24).
Transient Transfection Experiments—The cDNA fragments
coding for hDAAO and pLG72 were inserted into the
pEGFP-C3 (Clontech Laboratories) vector between theHindIII
and EcoRI restriction sites in-frame with the gene coding for
EGFP. The HindIII and EcoRI restriction sites were inserted
at the ends of hDAAO and pLG72 cDNA by mutagenic PCR
using the pET11-hDAAO (19) and pET11-G72 (18), respec-
tively, as templates. TheU87 human glioblastoma cells (ATCC)
were transfected by using the ExGen 500 Transfection reagent
(Fermentas Life Sciences) as suggested by the supplier. Three
micrograms of pEGFP-C3, pEGFP-C3-hDAAO, and pEGFP-
C3-pLG72 eukaryotic expression constructs were transfected
into 2  105 cells/well. The expression of the fusion proteins
was monitored by detecting green fluorescence protein emis-
sion; after 19 h of incubation, the cells were collected, counted,
washed once in PBS, and stored at80 °C for further analysis.
To determine cellular D- and L-serine levels, about 5  105
transfected cells were resuspended in 1 ml of ice-cold 5% tri-
chloroacetic acid, sonicated, and centrifuged for 30 min at
13,000 rpm. The soluble fraction was extracted with water-sat-
urated ether and neutralized with NaOH before precolumn
derivatization with o-phthalaldehyde/N-acetyl-L-cysteine in
borate buffer (12). D- and L-serine were resolved byHPLC chro-
matography on a 5-m Waters C8 (4.6  250 mm) reverse-
phase column eluted under isocratic conditions using 100 mM
sodium acetate buffer, pH 6.2, 1% tetrahydrofuran at 1 ml/min.
The compounds were identified and quantified on the basis
of retention times and peak areas compared with those asso-
ciated with D- and L-serine as standards. Linearity was deter-
mined by injecting increasing concentrations of amino acids
(20–100 pmol); the calibration curves were used to deter-
mine the amount of amino acids in the experimental sam-
ples. The analyses were replicated five times for each condi-
tion, and statistical analyses were performed using
Kaleidagraph software (Synergy Software). Variation
between groups was evaluated by one-way analysis of vari-
ance, and post-hoc significance tests were performed using
Student’s t test. Significance was assessed at p  0.05.
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DAAO activity measurements on control and transfected
U87 cell crude extracts were performed by the Amplex Ultra-
Red assay kit (Invitrogen) based on the detection ofH2O2 by the
peroxidase-mediated oxidation of the fluorogenic Amplex
UltraRed dye. Cells were suspended in ice-cold 50 mM sodium
phosphate buffer, pH 7.4, containing 1 M pepstatin, 2 M leu-
peptin, and 10 M FAD, sonicated, and centrifuged at 13,000
rpm for 10 min (4 °C); 300 l of these solutions (corresponding
to 2  104 cells) were diluted 1:2 in the activity assay solution
containing 50 M Amplex UltraRed, 0.2 units/ml horseradish
peroxidase, 10mMNaN3, 10MFAD, 50mMD-serine and incu-
bated for 30 min at room temperature in the dark. The reac-
tions were blocked by adding 120 l of Amplex UltraRed stop
reagent, and fluorescence emission at 590 nm was measured.
For each sample a control without the substrate D-serine was
prepared; DAAO activity was expressed as the difference in
fluorescence emission between sample and control assay mix-
tures. Furthermore, 1 mM sodium benzoate (a well known
DAAO inhibitor) (4, 5) was added to determine whether the
fluorescence changes were effectively due to DAAO activity. A
calibration curve was obtained by adding known amounts of
recombinant hDAAO to U87 crude extracts (0.02–0.4-milli-
unit range). Statistical analyses were performed as reported
above.
RESULTS
Effect of pLG72 on DAAO from Pig Kidney—By using yeast
two-hybrid experiments, DAAO was previously identified as a
protein that interacts with pLG72 (3). This interactionwas con-
firmed in vitro, but these experiments were performed essen-
tially on porcineDAAO, e.g. by binding to a columnwith immo-
bilized pkDAAO. Similarly, by measuring the enzymatic
activity of pkDAAO in the presence of increasing amounts of
pLG72, the latter was suggested to be an activator of DAAO.
The only experiment performed on hDAAO was a glutathione
S-transferase pull down of pLG72 using immobilized hDAAO,
which demonstrates the interaction between the two proteins
(3). The amino acid sequence for the hDAAO protein is more
than 80% identical to that of pkDAAO. However, hDAAO can
be distinguished from pkDAAO because of the weaker FAD
binding and the stable homodimeric state even in the apopro-
tein form (19). First, we repeated the experiments from (3)
using commercial pkDAAO and our recombinant pLG72 pro-
tein. A signal corresponding to the interaction of pkDAAO to
pLG72 was evident in Far Western blot experiments (supple-
mental Fig. 1A, left). As shown in supplemental Fig. 2A and
using the same experimental conditions reported byChumakov
et al. (3), the activity of pkDAAO (45 g/ml) decreased in the
presence of pLG72 (270 g/ml), whereas adding BSA as a con-
trol to pkDAAO did not affect the activity of the flavoprotein.
The inactivation of DAAOby pLG72was even faster at increas-
ing concentrations of NLS, a detergent required to solubilize
pLG72 (18). Furthermore, the addition of pLG72 directly into
the DAAO activity assay solutions (i.e. without any previous
incubation between the two proteins) did not modify pkDAAO
activity (0.51  0.06 and 0.53  0.09 units/ml in the absence
and in the presence of pLG72, respectively). In all cases, the
pkDAAO activity in the presence of pLG72 was higher if
there was an excess of free FAD in the assay solution,
although the presence of free FAD did not alter the time course
of enzyme inactivation. These results confirm the previously
reported in vitro interaction between pkDAAO and pLG72 (3)
but fail to show any enzymatic activation by pLG72. In contrast,
we showed that pLG72 inactivates pkDAAO.
Determination of pLG72 Binding Affinity to hDAAO—To
verify the inferred interaction of pLG72 to hDAAO in vitro (3),
we first used FarWestern blot analysis using purified recombi-
nant proteins (lanes 1 and 2 in Fig. 1A). A signal corresponding
to the interaction of hDAAOtopLG72was evident under dena-
turing conditions when nitrocellulose membranes were over-
laid with hDAAO and probed with monospecific polyclonal
anti-hDAAOantibodies after SDS-PAGE separation and trans-
blotting of pLG72. The signal was even more apparent under
native conditions as revealed by dot FarWestern blot (wherein
pLG72 was adsorbed onto a nitrocellulose membrane) (supple-
mental Fig. 1A, central panel). The immuno-recognition is
strictly specific for the mammalian DAAO as no signal was
observed using DAAO from yeast (RgDAAO) (supplemental
Fig. 1A, right panel).
The pLG72 binding to hDAAO was then followed by gel
permeation chromatography on a Superdex 200 column; the
separations were performed using a fixed amount of pLG72 (25
nmol) and increasing amounts of hDAAO (from5 to 200 nmol).
The elution volumeof hDAAOwas shifted from14.2 to 12.8ml,
i.e. from the homodimeric state of 80 kDa to a form of200
20 kDa (Fig. 1B). The presence of both pLG72 and hDAAO in
the 12.8-ml peak was demonstrated by SDS-PAGE electro-
phoresis (lane 4 in Fig. 1A). The saturation of the area of the
peak at 12.8 ml was obtained at an 2 hDAAO monomers:1
pLG72 monomer ratio (see the intercept of the straight lines in
Fig. 1C, top panel). As a control of the specificity of this inter-
action, the same experimentwas performed using RgDAAO; its
elution volume (14.5 ml) was not affected by the addition of
pLG72 (Fig. 1D). Next, we performed the same experiments
using the apoprotein form of hDAAO; the elution profiles
resemble the ones obtained for the holoenzyme. The area of the
12.3-ml peak corresponding to the protein complex increased
with the amount of added apohDAAO; from the plot reported
in Fig. 1C, bottom panel, an 2:1 apohDAAO:pLG72 stoichi-
ometry is evident. The stoichiometry of hDAAOpLG72 com-
plex formation was further confirmed using densitometric
analysis to quantifying the amount of the two proteins in the
fraction eluted at the volume corresponding to the complex; for
both holo- and apoprotein forms, a hDAAO:pLG72molar ratio
of 1.93  0.15 is evident (Fig. 1E). These results demonstrate
that pLG72 interacts with both the holo- and the apoprotein
form of hDAAO to yield a similar complex.
Analogously, quantitative pulldown experiments performed
using anti-pLG72 antibodies on protein samples containing a
fixed amount of pLG72 (0.1 nmol) and increasing concentra-
tions of hDAAO (0–0.8 nmol) showed a saturation of the
amount of immunoprecipitated hDAAO at a hDAAO:pLG72
ratio of 2:1 (see Fig. 1F). Finally, similar results were obtained
using spectroscopic methods, e.g. by following the changes in
fluorescence of the hydrophobic probe 8-anilino-naphthalene-
1-sulfonate during titration of a fixed amount of pLG72 with
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increasing hDAAO concentrations (see the supplemental
materials).
The apparent affinity for the hDAAOpLG72 complex for-
mation was assessed by means of surface plasmon resonance
using the BIAcore technology. By fluxing pLG72 solutions at
different concentrations over a sensor chip surface with immo-
bilized hDAAO, a specific signal was detected (supplemental
Fig. 1B); an apparentKD of 8.3 106 M for the hDAAOpLG72
complex formation was calculated. The injection of several
other protein solutions (CK2, CK2, Bud32) and also native
and denatured BSA (boiled or incubated at 50 °C for 30 min) as
negative controls did not induce any significant signal (data not
shown). The same experiments reported in supplemental Fig.
1Bwere also performed using the apohDAAO, resulting in sim-
ilar experimental traces (not shown). The BIAcore experiments
were also conducted by fluxing soluble hDAAO on an immobi-
lized pLG72-chip; this approach confirmed theKD value for the
hDAAOpLG72 complex and demonstrated the specificity of
pLG72 binding to hDAAO as RgDAAO displayed a very low
binding capability (supplemental Fig. 1C) evenwhen injected at
a 10-fold higher concentration.
Effect of pLG72 Binding on hDAAO Stability—The effect of
pLG72 on hDAAO stability was analyzed by mixing a fixed
amount of hDAAO (50 M) with increasing concentrations of
pLG72 (at a 0.06% NLS concentration, at which pLG72 is fully
soluble and hDAAO is stable, supplemental Fig. 2B). In the
FIGURE 1. Analysis of pLG72 binding to DAAO by gel permeation chromatography (A–E) and quantitative pulldown experiments (F). A, SDS-PAGE
analysis of purified pLG72 (5 g, lane 1) and hDAAO (5 g, lane 2), of a mixture of hDAAO and pLG72 (lane 3), and of the hDAAOpLG72 complex isolated by
gel-permeation chromatography (lane 4). Lane 5, standard proteins. B, top panel, elution profiles of gel permeation chromatography of purified hDAAO (left, y
axis) and pLG72 (right, y axis) proteins (upper) and of mixtures containing 25 nmol of pLG72 and different amounts of hDAAO (from 12.5 to 150 nmol, lower).
Bottompanel, example of analysis of peaks fromgel permeation chromatography of 25 nmol of hDAAOand 25 nmol of pLG72 by nonlinear curve fitting (using
PeakFit software); shown is deconvolution of the peaks corresponding to pLG72 (15.0 ml), hDAAO (14.2 ml), and the complex (12.8 ml). C, effect of hDAAO
concentrationon the areaof the 12.8-ml peak corresponding to thehDAAOpLG72 complex for holo-hDAAO (upper) and at 12.3ml for apohDAAO (lower). Data
from theelutionprofiles reported inpanel Bwere analyzedas reportedunder “Experimental Procedures.”D, control experiment showing that yeastDAAOdoes
not form a complex with pLG72; (upper) elution profiles of purified RgDAAO (left, y axis) and pLG72 (right, y axis); lower elution profile of a mixture containing
25nmolofpLG72and50nmolof RgDAAO.mAU,milliabsorbanceunits. E, results fromdensitometric analysis of thebands corresponding tohDAAOandpLG72
after SDS-PAGE separation of the proteins eluted in the peak corresponding to the hDAAOpLG72 complex (see lane 4 in panel A), expressed as hDAAO:pLG72
molar ratio for holo- (upper) and apohDAAO (lower). Data reported inpanels C and E are the averageof threedeterminations. Noteworthy, in the absenceofNLS
in the elutionbuffer, the addition of pLG72 shifted the elution volumeof hDAAO from14.1 to 8.1ml (close to the void volumeof the column), i.e. fromadimeric
to a polymeric state (data not shown), reaching a maximum at a hDAAO:pLG72 ratio of between a 2:1 and 4:1 ratio. ND, not determined. F, results from
densitometric analysis of the band corresponding to hDAAO precipitated by quantitative pulldown experiments performed using anti-pLG72 antibodies on
protein samples containing 0.1 nmol of pLG72 and increasing concentrations of hDAAO (0–0.8 nmol).
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absence of pLG72, hDAAO maintained more than 90% of its
initial activity after 21 h of incubation at 4 °C, whereas in the
presence of increasing amounts of pLG72 the enzyme activity
rapidly decreased (Fig. 2A). The effect of pLG72 on hDAAO
stability was similar, but the enzyme was more rapidly inacti-
vated when incubated at 25 or 37 °C. The presence of different
amounts of free FAD in the incubation mixture (10 or 500 M)
did not modify the time course of enzyme activity. As an addi-
tional control and under the same experimental conditions,
neither the addition of pLG72 to RgDAAO nor the addition of
BSA (soluble and denatured) to hDAAO modified the time
course of enzyme (in)activation (Fig. 2A). SDS-PAGE analyses
showed that the effect of pLG72 on the time course of loss of
hDAAO activity was not due to proteolysis or to precipitation
of the enzyme (no protein was detected in the pellet after cen-
trifugation at up to 24 h of incubation). Further evidence of a
destabilizing effect on hDAAOnative conformation induced by
pLG72 binding was derived from limited proteolysis experi-
ments. In fact, the half-time for cleavage of hDAAO by 10%
trypsin largely decreased from 7 to 3.5 min after adding an
equimolar amount of pLG72.
Effect of pLG72 Binding on hDAAO Activity—As a prelimi-
nary investigation, the initial rate of hDAAO reaction was
measured using the oxygen consumption assay on 100 mM
D-serine (a saturating substrate concentration) in the presence
of increasing concentrations of pLG72. As shown in supple-
mental Fig. 2C, the enzymatic activity only increased slightly in
the presence of a large amount of pLG72 and an excess of free
FAD in the assay mixture. By way of comparison, the activity
decreased at increasing pLG72 concentrations in the absence of
exogenous FAD in the assay mixture, i.e. under conditions at
which a fraction of hDAAO in the assay solution is present in
the apoprotein form (19). Interestingly, when the same meas-
urement was performed after preincubating hDAAO and
pLG72 for 30 min at 25 °C, the enzymatic activity always
showed a decrease and was completely abolished in the pres-
ence of an excess of pLG72 (at a hDAAO:pLG72 ratio1:2, Fig.
2B). The apparent kinetic parameters on D-serine, the putative
physiological substrate of hDAAOdetermined at 25 °C and21%
oxygen saturation (19), were not changed after the addition of
pLG72 (exogenous FAD did not affect these values either; see
supplemental Table 1).
The presence of pLG72 decreased the amount of hDAAO-
bound FAD that can be reduced by the substrate (i.e. the active
enzyme form). In fact, after incubation for at least 30 min (the
time required to achieve anaerobic conditions) with a stoichio-
metric amount of pLG72, only 55% of FAD was converted into
the corresponding reduced formwhen a large excess of D-serine
was added under anaerobic conditionswith respect to the flavin
reduced in the absence of pLG72 (supplemental Fig. 3A). This
value is further decreased at higher pLG72 concentrations.
Such an effect was not due to the depletion of FAD in solution
because of its binding to pLG72 (see below), as the same result
was obtained when an excess of free FAD was present in the
assay mixture; i.e. it represents an inhibition of the enzymatic
activity. This result correlates with the residual enzyme activity
measured after 30 min of incubation (see above and Fig. 2B).
FAD and CPZ Binding to hDAAO and pLG72—hDAAO
contains one molecule of noncovalently bound FAD per pro-
teinmonomer that can be easily isolated from the apoprotein by
dialysis in the presence of 1 M KBr (19). By measuring the
changes in protein fluorescence during titration of the apopro-
tein with FAD, a Kd of 10  4  106 M in 50 mM sodium
pyrophosphate buffer, pH 8.3, was estimated (19). This value is
significantly higher than the onemeasured for any other known
DAAO (in the 107–108 M range) (4, 5), raising the (unan-
swered) question of howmuch (active) holoenzyme of hDAAO
is present in vivo. In the presence of buffer A containing 0.06%
NLS, the Kd for FAD binding to apohDAAO increased to 40
3 106 M. Under the same conditions, the coenzyme binding
was not significantly affected by the presence of a stoichiomet-
ric amount or by a 4-fold molar excess of pLG72 (Kd value is
41.2  2.3 and 41.3  6.2 M, respectively). Interestingly, the
control experiments performed under the same conditions and
in the absence of hDAAO showed that the protein fluorescence
(at 340 nm) of pLG72 decreases at increasing FAD concentra-
tions (see supplemental Fig. 4A); a Kd value of 40  8 M has
been estimated. The pLG72FAD interaction was confirmed by
gel permeation chromatography on a Sephadex G25 column;
FIGURE 2.Effect of pLG72bindingonhDAAOactivity.A, effect of pLG72on
the time course of enzymatic activity of hDAAO (50 nmol/ml); hDAAO:pLG72
ratios 1:0 (F), 2:1 (Œ), 1:1 (), and1:2 (f) inbufferAcontaining0. 06%NLS. For
the sake of comparison, the effect of a 2-fold molar excess of boiled BSA on
hDAAO activity is also reported (E). When not shown, the error bars are
smaller than the symbols used. It is noteworthy that the inactivation
depended on the percentage of NLS in the incubationmixture; at 0.01% NLS
theDAAOenzymatic activitywasnot alteredby addingpLG72because at this
concentrationof detergentpLG72 is not soluble.B, effect of pLG72onhDAAO
activity after 30 min of preincubation. The enzymatic activity was measured
by the oxygen consumptionmethod on 100mM D-serine using fixed amount
of hDAAO (0.1 nmol/ml) to which increasing amounts of pLG72 were added
30 min before the assay. The activity was measured with (black bars) and
without (white bars) 200 M free FAD in the assay mixture. The same experi-
ment was carried out by measuring the residual DAAO activity without pre-
incubation with pLG72 (see panel C of supplemental Fig. 2).
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the cofactor elutes in the same fraction of pLG72 (the absorb-
ance spectrum of the eluate is shown in supplemental Fig. 4B).
The kinetic assay used to establish the amount of hDAAO-
bound FAD (see above)was also employed to assess the effect of
pLG72 on the rate of flavin binding to the apoprotein form of
hDAAO. The presence of a 1–5-foldmolar excess of pLG72 did
not significantly affect the rate constant of flavin binding to the
apoprotein of hDAAO (kobs  0.008  0.002 s1) but did
decrease the amount of reconstituted holoenzyme, reaching
values similar to those observed under static conditions (as
reported in Fig. 2B).
Using the same fluorescence analysis employed for detecting
the FAD binding, we demonstrated that pLG72 possesses a
binding site for molecules with large hydrophobic moieties. In
fact, a Kd value of 65 13 and 26 3 M was estimated for the
binding of FMN and riboflavin, respectively, whereas no bind-
ing was observed using AMP (which lacks the hydrophobic
isoalloxazine ring). Even the drug CPZ interacts with apo-
hDAAO and pLG72 (supplemental Fig. 4C); in both cases a Kd
of about 5Mwas estimated. CPZ is an aliphatic phenothiazine
and a widely used antipsychotic drug in the treatment of schiz-
ophrenia (its chemical structure resembles that of the isoallox-
azine ring of FAD) that has been shown to be an FAD compet-
itive inhibitor of pkDAAO (25, 26). The interaction between
hDAAO or pLG72 and CPZ is not tight enough to be pharma-
cologically relevant. The spectral analyses of the pLG72 inter-
action to hDAAOhave been published as supplemental data on
the JBC web site.
Effect of pLG72 or hDAAO Transient Transfection on D-Ser-
ine Concentration—To establish the relationship between
pLG72/hDAAO and the cellular concentration of D-serine,
human glioblastoma U87 cells were transfected with
pEGFP-C3 expression vectors encoding for EGFP, EGFP-
hDAAO, and EGFP-pLG72 proteins (average transfection yield
was30–40%; see supplemental Fig. 5A). D- and L-serine con-
centrations in the transfected cells were determined by HPLC
analyses (supplemental Fig. 5B). Because the concentration of
the serine isomers showed a significant sample-dependent var-
iability, the value was normalized to the L-serine concentration
by using the D-/L-serine ratio. The
D-/L-serine ratio determined on
control cells (nontransfected or
transfected with pEGFP-C3 plas-
mid  mock transfection)
decreased in the cells transfected
with the plasmid pEGF-C3-hDAAO
encoding for hDAAO from 13.0 
0.9 to 10.2 0.5% (n 5, p 0.05)
and did not show a statistically sig-
nificant change in those transfected
with the plasmid pEGFP-C3-pLG72
encoding for pLG72 and in the cells
cotransfectedwith the two plasmids
(showing in both cases a value of
13.4%, n  5, p  0.05, Fig. 3A).
Furthermore, the amount of
hDAAO activity in U87 control and
transfected cells was assessed using
the Amplex UltraRed assay. As shown in Fig. 3B, the fluores-
cence signal corresponding to hDAAOactivity increases inU87
cells transfected with the pEGF-C3-hDAAO plasmid, whereas
it is practically negligible in cells transfected with pEGFP-C3-
pLG72 plasmid and similar to the control in cells cotransfected
with the two plasmids. In samples that show a substantial enzy-
matic activity (control and hDAAO-transfected cells), the addi-
tion of the hDAAO inhibitor benzoate significantly decreases
the observed activity values. These results indicate that the level
of D-serine decreases after transient transfection of hDAAO in
U87 cells according to the function of this flavooxidase in D-ser-
ine catabolism; this effect is not observed after the transfection
of pLG72 in the same cells, further indicating that pLG72 is not
an activator of hDAAO.
Localization of hDAAO and pLG72—The results of all the
aforementioned experiments suggest that pLG72 interactswith
hDAAO and acts as an endogenous modulator of this enzyme.
We first checked for the presence of the two proteins in human
cortex. Western blot analysis on crude extracts from human
brain cortex samples using anti-DAAO antibodies showed the
presence of a band at a molecular mass of 40 kDa (lane 2 in
Fig. 4A, top panel; detection limit of 0.005g) corresponding to
that of native hDAAO (Mr 39,411). When the same analysis
was performed using anti-pLG72 antibodies, no bands were
evident in the crude extract (detection limit of 0.02 g),
whereas a band at26 kDa, corresponding to pLG72 (18), was
observed in the corresponding unsoluble fraction (see lane 4 in
Fig. 4A, bottom panel). When the same analyses were per-
formed in the presence of preabsorbed antibodies, no signals
were detected (see controls in Fig. 4A), thus confirming the
specificity of the recognition.
Immunoprecipitation of hDAAO from human cortex
extracts was performed using an amount of sample 50-fold
higher than in the Western blot experiments (10 versus 0.2 mg
of protein), rabbit anti-hDAAO antibodies, and the TrueBlot
system; the precipitated proteins were analyzed by SDS-PAGE
andWestern blot. By using anti-hDAAO antibodies, two bands
were identified; one at 40 kDa (the intact hDAAO) and
another at an 6-kDa lower molecular mass (that we propose
FIGURE3.Dependenceof D-serine concentrationandDAAOactivity inU87 cells transfectedwithhDAAO
and/or pLG72. The data are reported as the means  S.E. A, summary histogram of the D-/L-serine ratio
(percentage) in U87 control cells and in the same cells transfected with hDAAO, pLG72, or co-transfected with
both plasmids (n 5); see supplemental Fig. 5 for details. The change was demonstrated to be significant for
hDAAO (p 0.004) andnot significant for pLG72 and co-transfected cells.CTRL, control. B, summary histogram
of the DAAO activity (determined by means of the Amplex UltraRed assay and expressed as fluorescence
change at 490nmper 10,000 cells) inU87 control cells and in the same cells transfectedwith hDAAO, pLG72, or
co-transfected with both plasmids (n  6). Black and white bars report the activity values determined in the
absenceand in thepresenceof 165Msodiumbenzoate asDAAO inhibitor, respectively. The change inactivity
with respect to the control was demonstrated to be statistically significant for hDAAO (p  0.012) and not
significant for pLG72 and co-transfected cells.
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FIGURE 4. hDAAOand pLG72 are both present in astrocytes of the human cortex. A, immunoblot analysis of protein extracts from human cortex. Top
panel, 0.01 g of purified hDAAO (lanes 1 and 3) and 200 g of total proteins of extracts from human cortex (lanes 2 and 4) were analyzed using
anti-DAAO antibodies. For lanes 3 and 4, the antibodies were preadsorbed with a 1:350 molar ratio of hDAAO. Immunolabeling with anti-DAAO
antibodies demonstrates the presence of a band at 40 kDa in the crude extracts (lane 2). Bottom panel, 0.05 g of purified pLG72 (lanes 1 and 5) and 200
g of total proteins of soluble extracts (lanes 2, 3, and 6) and pellets (lanes 4 and 7) from human cortex were analyzed using anti-pLG72 antibodies (lanes
1–4) and anti-pLG72 antibodies pre-adsorbed with a 1:1200 molar ratio of pLG72 (lanes 5–7). Purified recombinant pLG72 was added in sample 3.
Immuno-recognition with anti-pLG72 antibodies showed bands at20 kDa in the presence of purified recombinant pLG72 (lanes 1 and 3) and at26
kDa in the unsoluble fraction (lanes 4), thus indicating that the amount of soluble pLG72 in crude extracts is below the detection limit (0.02 g/lane).
When antibodies were preabsorbed before immunolabeling, no signal was detected (lanes 5–7). B, co-immunoprecipitation of hDAAO and pLG72 using
anti-hDAAO antibodies (upper) and anti-pLG72 (lower), 500l of human cortex extract (20 mg protein/ml: lanes 2, 3, and 5) and the TrueBlot system. The
membrane corresponding to the precipitated sample was at first developed using anti-hDAAO antibodies (lanes 1–3) and, after stripping, using
anti-pLG72 antibodies (lanes 4–7). Lane 1, 0.01g of purified hDAAO; lane 4, 0.05g of purified pLG72. Lane 6 upper, the same sample as in lane 5 (crude
extract) with 0.05g of purified recombinant pLG72 showing the bands corresponding to recombinant (20 kDa) and native (26 kDa) pLG72. Lane 6 lower,
immunoprecipitation performed using anti-pLG72 antibodies on 0.04g of purified pLG72 treated as the crude extract and showing the band at 20 kDa
corresponding to recombinant pLG72. Controls, lanes 3 and 7 contain the same amount of anti-hDAAO (upper) or anti-pLG72 (lower) antibodies (Ab) used
for immunoprecipitation (IP). C and D, confocal analysis of the cellular distribution of hDAAO and pLG72 in the human cortex. Red channel, Alexa Fluor
594; green channel, Alexa Fluor 488. hDAAO and pLG72 (red channel) are both found throughout the cerebral wall. GS, GFAP, and S100 (not shown) are
also present (green channel) in the cerebral wall. Note that GS is present in the cell bodies, whereas GFAP (and S100) stain is also localized in the
processes of astrocytes. The results reported in panels C and D suggest that both hDAAO and pLG72 reside in the same cells. The analysis of the
distribution of the two proteins reported in panel E support this hypothesis; red (hDAAO) and green (pLG72) channels overlay revealed a net co-
localization of signal patterns, strongly indicating the presence of hDAAO and pLG72 inside the same astrocytes. Overlays of red and green channels
revealed strong yellow spots that support co-localization and the presence of hDAAO and pLG72 in astrocytes. Scale bars 25 m for all panels except
for zooms (10 m).
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as a proteolytic fragment of hDAAO and which is currently
being characterized) (Fig. 4B, top, left panel, lane 2). The same
membranewas thendeveloped by using anti-pLG72 antibodies;
a band at26 kDa was detected, corresponding to that identi-
fied in the insoluble fraction from crude extracts of human
brain cortex and confirming a lower electrophoreticmobility of
native, nonrecombinant pLG72 (lane 4, Fig. 4A, bottom panel).
The same results were obtained when the experiment was car-
ried out using anti-pLG72 antibodies to coimmunoprecipitate
the protein complex (see Fig. 4B, bottom panel). No signals
were detected if the primary antibodies or the crude extracts
were omitted (IgG-only, see lanes 3 and 7 in Fig. 4B), thus con-
firming the specificity of the recognition. This finding indicates
that hDAAO and pLG72 interact in human cortex.
Wenext analyzed the cellular distribution of the twoproteins
in slices from human cortex. Immunostaining displayed a
homogeneous distribution of DAAO throughout the layers of
the human cerebral wall, showing a pattern that seemed to
highlight parts of certain cell bodies (Fig. 4C, red channel). It has
been proposed that DAAO localizes in astrocytes in the central
nervous system (26–28). By using double immunostaining
experiments in which hDAAO labeling is paired with GS or
with GFAP, two well known markers of the astroglial lineage,
we demonstrated the presence ofDAAO in astrocytes. The pat-
tern of GS staining was quite similar to that of DAAO through-
out the cerebral wall (Fig. 4C, top panel, green channel). On the
other hand, GFAP staining revealed clearly labeled cell bodies
with processes (Fig. 4C, bottompanel, green channel). Although
the GFAP staining is found throughout the cerebral wall, it is
more pronounced and denser at the surface of the cortex at the
level of the subpial layer. Comparison of the two glial markers
with hDAAO confirmed the strictly astrocytic localization of
this flavoenzyme. On the double immuno-stains, DAAO was
absent in the subpial layer (Fig. 4C, merged panels). No signal
for hDAAO, GFAP, or GSwas observed in control experiments
(data not shown). Immunofluorescent staining for pLG72
revealed the presence of the protein throughout the cerebral
wall, with a pattern resembling that of hDAAO (compare the
red channels on Fig. 4,C andD). A comparison with GS, GFAP,
or S100 (a further glial marker) clearly demonstrates that
pLG72 is distributed in the astrocytes (not shown). At higher
magnifications hDAAO and pLG72 were both concentrated
mostly in the cell bodies, with no signal detected in the pro-
cesses of astrocytes (Fig. 4,C andD, zoom panels). Experiments
in brain slices suggested that both proteins should be present in
the same astrocytes. We confirmed this hypothesis by showing
a clear colocalization of the two proteins in the same cells (Fig.
4E,merged panels).
To further analyze the subcellular distribution of pLG72 and
hDAAO, we next used cultured human astrocytes. For hDAAO
an abundant and punctuate signal was found in the cultured
astrocytes (Fig. 5); the protein was widely distributed through-
out the cytoplasm. The DAAO flavoprotein was previously
identified as a resident protein of peroxisomes (27, 29, 30) that
can be unmasked by PMP70, a component of peroxisomal
membranes. In astrocytes, PMP70was abundant, yielding a sig-
nal pattern that resembled that of hDAAO (Fig. 5A, red chan-
nel). In fact, the overlay of the red channel onto the green one
revealed a net (although partial) colocalization of hDAAO and
PMP70, particularly in the perinuclear region of the cell (Fig.
5A, top panel,merged, and zoompanels). This latter observation
confirmed that in human astrocytes DAAO is largely present in
the peroxisomes but also revealed that a significant amount of
this flavoenzyme is localized outside these organelles. Impor-
tantly, the putative nonperoxisomal DAAO form might possi-
bly be related to the electrophoretically more mobile form of
the protein observed in the immunoprecipitation experiment
on the crude human cortex extract (see Fig. 4B); further analy-
ses will be undertaken to characterize this protein form or
hDAAO proteolytic product. On the other hand, an only mar-
ginal overlap in signal was observed between hDAAO and 58K
protein (amarker of theGolgi complex) andMitoTracker green
FM (a mitochondrion-selective stain) (Fig. 5, B and C).
Concerning the subcellular distribution of pLG72, immun-
ofluorescent staining demonstrated a perinuclear and tubular
pattern of distribution that resembles the Golgi apparatus net-
work (Fig. 5A, bottom panel). Indeed, pLG72 has previously
been proposed to be present in this compartment (3). Thus, we
analyzed the distribution of pLG72 versus the pattern of a 58K
Golgi protein and versus GM130, a protein associated with the
membrane of the cis-Golgi network (31). AlthoughGM130 also
displays its typical tubular pattern, no colocalization of pLG72
with GM130 was detected in the cultured astrocytes (not
shown), thus excluding the presence of pLG72 inside the cis-
Golgi network. On the other hand, a partial perinuclear over-
lapping in the signal pattern was observed for the 58K protein
(Fig. 5B, bottom panel, merged panel), suggesting that pLG72
could transiently pass through the Golgi apparatus. Further-
more, a strong punctuate immunostaining for pLG72 is present
outside this subcellular compartment, indicating a cytosolic
localization of pLG72 (Fig. 5B, bottom panel,merged panel). No
significant overlap in signal was observed between pLG72 and
PMP70 (Fig. 5A, bottom panel) or between pLG72 and Mito-
Tracker green FM (Fig. 5C, bottom panel). Furthermore, no
colocalization was detected between hDAAO or pLG72 and
lysosome-associated membrane protein 2 as a marker of the
lysosomes (data not shown).
Finally, we compared the distribution of hDAAOwith that of
pLG72 (Fig. 5D). Here, we only rarely observed colocalization
patterns in resting cells between pLG72 and hDAAO and,
therefore, could not accurately quantify this distribution. In
particular, we observed that only 5% of the cells display colocal-
ization patterns, with amean average of 8.1% colocalization; the
cell displayed in Fig. 5D shows a partial overlap of 10% between
hDAAO and pLG72. Thus, it is more likely that pLG72 interac-
tion with hDAAO is driven by specific spatiotemporal stimuli,
the features of which remain to be discovered.
DISCUSSION
Schizophrenia is a severe psychiatric disorder that affects
nearly 1% of the world population and accounts for about 2.5%
of healthcare costs. With the discovery of the correlation
between G72 and DAAO genes and schizophrenia (both as an
individual gene and synergistically), a biochemical system was
proposed that could be responsible for the major symptoms of
this psychiatric disorder (3). After the report by Chumakov
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FIGURE 5. Confocal analysis of the subcellular distribution of hDAAO and pLG72 in cultured human astrocytes. Red channel, Alexa Fluor 594 or 647; green
channel, Alexa Fluor 488. A, the immunofluorescence staining of hDAAO and pLG72 (green channel) are compared with the distribution of the peroxisomal marker
PMP70(redchannel).Themergedandzoompanelsshownooverlap insignalbetweenpLG72andPMP70stainingandhighlightaco-localizationofhDAAOandPMP70,
also revealing that a significant amount of hDAAO is present outside peroxisomes. B, subcellular distribution of hDAAO and pLG72 (red channel) with respect to 58K
Golgi protein (green channel). The overlay of the two channels in the merged and zoom panels demonstrates a partial perinuclear overlapping in pLG72 and 58K
protein signalpatternseventhoughastrongpunctuatecytosolic immunostaining isalsoobserved.Onlymarginaloverlap insignals isobservedbetweenhDAAOand
58K protein. C, the immunofluorescence signals of hDAAO and pLG72 (red channel) are compared withMitoTracker green FMmitochondrion-selective stain (green
channel). ForbothhDAAOandpLG72,nosignificantco-localizationwithMitoTracker isobserved.D, comparisonof thesubcellulardistributionofhDAAO(redchannel)
and pLG72 (green channel). In themerged and zoompanels a partial co-localization (10%) is evident. Scale bars 40mfor all panels except for zooms (10m).
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et al. (3), at least 11 genetic studies reported on the association
between markers near G72 and DAAO genes and various phe-
notypes. In particular, a significant association ofG72with both
schizophrenia and bipolar affective disorders and of DAAO
with schizophrenia in at least two different ethnic groups was
reported; for a recent review, see Ref. 32. Among the identified
single nucleotide polymorphisms, no changes in the coding
region of hDAAO were identified that can relate loss/gain of
functionality and/or altered levels of expression with schizo-
phrenia susceptibility. Concerning G72, only single nucleotide
polymorphism rs2391191, corresponding toM-15 in the report
from Chumakov et al. (3), contains a mutation (Arg3 Lys) in
the coding region; indeed, a recent study did not find an asso-
ciation between this polymorphism and schizophrenia (33).
Identification of the levels of hDAAOor pLG72 expression and
of hDAAO activity in schizophrenia patients will help validate
the inferred physiopathological model.
Our investigations confirm the interaction between human
proteins pLG72 and DAAO but failed to reproduce the effects
of pLG72 binding to pkDAAO reported by Chumakov et al. (3);
specifically, pLG72 did not activate pkDAAO. By using a variety
of experimental methods, we demonstrated that pLG72 inter-
acts specifically with both the holo- and apoprotein forms of
mammalian DAAO, yielding an 200-kDa complex consti-
tuted by 2 hDAAO homodimers (2  80 kDa) and 2 pLG72
molecules (2  20 kDa); Kd for the complex formation is
8  106 M.
pLG72 binding did not affect the kinetic parameters of the
reaction catalyzed by hDAAOon D-serine, the affinity for coen-
zyme, or the rate constant of FAD binding to the apoprotein.
The main effect observed was a faster time course of hDAAO
inactivation when an excess of pLG72 was present, which we
attributed to the decrease in the holoenzyme (active) form. In
fact, the amount of cofactor bound to the enzyme (the only FAD
molecules that can be reduced by the substrate) decreased after
the pLG72hDAAO complex was formed (compare Fig. 2B and
supplemental Fig. 3A). Visible absorbance and near-UV CD
spectroscopy also showed that the binding altered the tertiary
structure of hDAAO.
In human brain slices from cortex, we identified hDAAOand
pLG72 in the same astrocytes. Furthermore, the coimmuno-
precipitation of the two proteins from human cortex extracts
and the partial subcellular colocalization of hDAAOandpLG72
in human glial cells further supports the possibility of interac-
tion between these two proteins in vivo, suggesting that pLG72
might indirectlymodulate NMDA receptor function (at least in
cortex), controlling the levels of D-serine by acting on hDAAO.
Chumakov et al. (3) proposed pLG72 as an activator of
hDAAO (Fig. 6, top), and therefore, they hypothesized that the
onset of schizophrenia may result from the overexpression of
pLG72, which induces hyperactivation of DAAO and, ulti-
mately, decreases D-serine concentrations at the synapse (and
the amount of NMDA receptors that can be activated). In our
opinion, the role of pLG72 is more complex. Initially, pLG72
binding does not affect hDAAO functionality but, rather, mod-
ifies its tertiary structure and results in a time-dependent inac-
tivation of the flavoenzyme. We propose that this binding
switches off hDAAO activity and under normal conditions pre-
vents glial D-serine frombeing fully degraded. This “slow”mod-
ification of hDAAO activity by pLG72 binding correlates with
the low, inferred in vivo efficiency of this flavoenzyme (due to
the weak cofactor binding and low turnover number) (19) and
with the long half-life (16 h) of D-serine in brain (8). We pro-
pose that alterations in the expression of pLG72 (e.g. a hypoex-
FIGURE 6. Hypothesis of the role of hDAAO and pLG72 on the D-serine bioavailability at glutamatergic synapses under normal and pathological
conditions. Glutamate is released by the presynaptic neuron into the synaptic space after the depolarization of nerve terminals, yielding the activation of
non-NMDA receptors on the membrane of the postsynaptic neuron and, subsequently, an increase in cytoplasmic concentration of Ca2. D-Serine is then
releasedby the glial cells and, togetherwith glutamate, activatesNMDA receptors on themembrane of the postsynaptic neuron, leading to the opening of ion
channels. The Ca2 entry induces several possible intracellular responses, e.g. it activates nitric-oxide synthase that produces NO, which can diffuse to the
neighboring cells where it is proposed to inhibit serine racemase and (probably) activate DAAO, thus decreasing the local concentration of D-serine (8). Upper
loop, hypothesis of involvement of hDAAO and pLG72 in schizophrenia according to Chumakov et al. (3) in which pLG72 is an activator of hDAAO; under
pathological conditions an overexpression of pLG72 leads to an increase in hDAAO activity that decreases the local concentration of D-serine. Lower loop,
our hypothesis, in which pLG72 modulates the amount of active hDAAO acting on the stability of the holoenzyme. An abnormal, low expression of pLG72
under pathological conditions could result in hyperactivation of hDAAOanddecrease D-serine concentration. Importantly, in both hypotheses the decrease in
D-serine concentration results in a lower amount of activatedNMDA receptors (NMDA-R) and, thus, in a hypofunction of the glutamatergic neurotransmission.
Filled dots, glutamate; triangles, D-serine; open dots, Ca2; AMPA-R, -amino-3-hydroxyl-5-methyl-4-isoxazolpropionic acid receptor.
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pression in schizophrenia patients) could significantly decrease
the D-serine concentration in brain due to abnormally high
activity of hDAAO (Fig. 6, bottom). Importantly, our hypothesis
also explains the beneficial effects of D-serine treatment in
schizophrenia patients (17). Moreover, our findings and those
of Chumakov et al. (3) contradict the conclusions recently
reported by Kvajo et al. (34), which suggested that pLG72 has a
role in modulating mitochondrial functions.
The availability of the pLG72-hDAAO protein complex in
solution and under physiological conditions represents an ideal
system for finding small molecules that inhibit and/or modu-
late this protein-protein interaction. Demonstration of a spe-
cific correlation between the D-serine-pLG72-hDAAO bio-
chemical pathway, glutamatergic neurotransmission, and
relevant psychiatric disorders such as schizophrenia will pro-
mote therapeutic approaches targeting the molecular patho-
genesis rather than the symptoms.
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